Redefining Acute Coronary Syndrome Therapy
Patients with acute coronary syndromes who received a low dose of the oral anticoagulant rivaroxaban, when substituted for aspirin in dual antiplatelet therapy (DAPT), had a similar risk of clinically significant bleeding as patients receiving standard DAPT in a phase 2 trial published in The Lancet. Nearly 10% of patients treated with standard DAPT therapy--aspirin combined with P2Y12 inhibitors clopidogrel or ticagrelor--still experience major cardiovascular events. Research is addressing the possibility of adding antithrombotic agents such as rivaroxaban to aspirin and clopidogrel to reduce cardiovascular adverse events in such patients. However, previous studies have suggested that the addition of antithrombotic agents to DAPT causes an excessive risk of bleeding..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:317 |
|---|---|
| Enthalten in: |
The journal of the American Medical Association / Englische Ausgabe - 317(2017), 20, Seite 2054-2054 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Slomski, Anita [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute coronary syndromes |
|---|
| doi: |
10.1001/jama.2017.6081 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1994213663 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1994213663 | ||
| 003 | DE-627 | ||
| 005 | 20230715052714.0 | ||
| 007 | tu | ||
| 008 | 170721s2017 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1001/jama.2017.6081 |2 doi | |
| 028 | 5 | 2 | |a PQ20170901 |
| 035 | |a (DE-627)OLC1994213663 | ||
| 035 | |a (DE-599)GBVOLC1994213663 | ||
| 035 | |a (PRQ)a1128-3ebe6fa736594ee84dcb148cdfc933f078baa84a57363d390dde727335e579170 | ||
| 035 | |a (KEY)0027940420170000317002002054redefiningacutecoronarysyndrometherapy | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 100 | 1 | |a Slomski, Anita |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Redefining Acute Coronary Syndrome Therapy |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Patients with acute coronary syndromes who received a low dose of the oral anticoagulant rivaroxaban, when substituted for aspirin in dual antiplatelet therapy (DAPT), had a similar risk of clinically significant bleeding as patients receiving standard DAPT in a phase 2 trial published in The Lancet. Nearly 10% of patients treated with standard DAPT therapy--aspirin combined with P2Y12 inhibitors clopidogrel or ticagrelor--still experience major cardiovascular events. Research is addressing the possibility of adding antithrombotic agents such as rivaroxaban to aspirin and clopidogrel to reduce cardiovascular adverse events in such patients. However, previous studies have suggested that the addition of antithrombotic agents to DAPT causes an excessive risk of bleeding. | ||
| 650 | 4 | |a Reagents | |
| 650 | 4 | |a Anticoagulants | |
| 650 | 4 | |a Therapy | |
| 650 | 4 | |a Patients | |
| 650 | 4 | |a Clinical trials | |
| 650 | 4 | |a Disorders | |
| 650 | 4 | |a Oral cavity | |
| 650 | 4 | |a Risk | |
| 650 | 4 | |a Aspirin | |
| 650 | 4 | |a Clopidogrel | |
| 650 | 4 | |a Bleeding | |
| 650 | 4 | |a Inhibitors | |
| 650 | 4 | |a Acute coronary syndromes | |
| 650 | 4 | |a Side effects | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of the American Medical Association / Englische Ausgabe |d Chicago, Ill. : American Medical Association, 1883 |g 317(2017), 20, Seite 2054-2054 |w (DE-627)129077798 |w (DE-600)2958-0 |w (DE-576)014410338 |x 0254-9077 |7 nnns |
| 773 | 1 | 8 | |g volume:317 |g year:2017 |g number:20 |g pages:2054-2054 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1001/jama.2017.6081 |3 Volltext |
| 856 | 4 | 2 | |u http://dx.doi.org/10.1001/jama.2017.6081 |
| 856 | 4 | 2 | |u https://search.proquest.com/docview/1907809132 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_252 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2414 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4082 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4309 | ||
| 951 | |a AR | ||
| 952 | |d 317 |j 2017 |e 20 |h 2054-2054 | ||